Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationMicrob. Pathog. 2000, 29(2):81-91
AbstractPneumococci cause infection by colonizing the nasopharynx and invading the mucosal surfaces. Infection models in mice, where the natural route of infection is mimicked, may be useful to study antibody mediated protection against pneumococcal pneumonia and bacteremia. We have established a pneumococcal pneumonia and bacteremia model in mice and investigated the protective capacity of human antibodies. Intranasal challenge with serotypes 1, 3, 6A and 8 caused lung infection and bacteremia which was lethal. Serotype 6B caused low, but detectable, infection and other serotypes tested were not virulent. Passive immunization with a human IgG preparation i.p. protected mice in a dose dependent manner against bacteremia caused by the virulent serotypes (except serotype 3) and partially or completely cleared pneumococci from the lungs of mice infected with serotypes 1, 6A and 8. Adsorption of antibodies with homologous capsular polysaccharides eliminated protection against disease but adsorption with cell wall polysaccharides (CWPS) did not. Furthermore, a good correlation was observed between protection of sera in vivo and opsonic activity in vitro. The results indicate that the model may be useful to analyse the levels, isotypes, specificity and other characteristics of human antibodies which protect against pneumococcal infection and to evaluate the protective potential of pneumococcal vaccine candidates.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.
- Authors: Saeland E, Jakobsen H, Ingolfsdottir G, Sigurdardottir ST, Jonsdottir I
- Issue date: 2001 Jan 15
- Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats.
- Authors: Stack AM, Malley R, Thompson CM, Kobzik L, Siber GR, Saladino RA
- Issue date: 1998 Apr
- Enhancement of Streptococcus pneumoniae serotype 6B infection in mice after passive immunization with human serum.
- Authors: Aaberge IS, Hvalbye B, Løvik M
- Issue date: 1996 Aug
- Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae.
- Authors: Johnson SE, Rubin L, Romero-Steiner S, Dykes JK, Pais LB, Rizvi A, Ades E, Carlone GM
- Issue date: 1999 Jul
- Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice.
- Authors: Saeland E, Vidarsson G, Leusen JH, Van Garderen E, Nahm MH, Vile-Weekhout H, Walraven V, Stemerding AM, Verbeek JS, Rijkers GT, Kuis W, Sanders EA, Van De Winkel JG
- Issue date: 2003 Jun 15